# CARTITUDE-4 (NCT04181827)

> A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04181827
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Cilta-cel; Pomalidomide; Bortezomib; Dexamethasone; Daratumumab
- Enrollment: 419
- Primary outcome: Progression Free Survival (PFS)

## Commentary we found

- YouTube: 221
- X threads: 218
- Podcasts: 104
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cartitude-4-nct04181827

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04181827", "email": "<work email>"}; the inbox owner confirms by the emailed link.